Despite the importance and frequency of levodopadecrease in the mean firing frequency of GPi neurones, although dyskinesias were induced only in the induced dyskinesias, little is known about their causal mechanisms. In this study, electrophysiological single-unit parkinsonian animals. In this situation, the improvement of parkinsonian motor abnormalities was correlated with recordings of the neuronal activity of the globus pallidus internalis (GPi), the main basal ganglia output structure, the decrease in GPi firing frequency, whereas firing pattern changes were concomitant with the onset of and the globus pallidus externalis (GPe) were recorded continuously in both normal and 1-methyl-4-phenyldyskinesias. Moreover, firing frequency seemed to be decreased excessively during dyskinesias. The results 1,2,3,6-tetrahydropyridine treated subhuman primates before and after the administration of three dopamine indicate that the electrophysiological mechanism of dyskinesia involves an excessive decrease in GPi firing agonists-apomorphine (a dopaminergic mixed agonist), SKF-38393 (a D 1 partial agonist) and piribedil (a D 2 /D 3 frequency and a modification of the firing pattern. However, the similarity between the induced decrease in agonist)-at doses known to induce dyskinesias in the parkinsonian monkey. Changes in both the firing firing frequency in normal and parkinsonian animals underlines the need for dopamine depletion in the frequency and the firing pattern were analysed in relation to behavioural modifications. In both the normal and induction of dyskinesias. the parkinsonian monkey, the three agonists induced a
Introduction
The discovery that the death of nigrostriatal dopaminergic into D 2 , D 3 and D 4 receptors (Sokoloff and Schwartz, 1995) . Receptors of the D 1 family are thought to be located on neurones is responsible for the debilitating motor syndrome observed in Parkinson's disease has led to the development neurones projecting to the globus pallidus pars internalis (GPi), whereas those of the D 2 family are found on neurones of replacement therapies. Levodopa remains the standard treatment for Parkinson's disease, although it induces longprojecting to the pars externalis of the globus pallidus (GPe) (e.g. Gerfen et al., 1990; Le Moine and Bloch, 1995) . term side-effects. The most common of these, dyskinesia, affects nearly 50% of patients after a duration of illness of Although the role played by these different receptors in the emergence of dyskinesia remains controversial (Bedard et al., 5 years (Marsden et al., 1982) , but its causal mechanisms remain unknown. Dopamine acts on striatal neurones through 1999), the main hypothesis is that dyskinesia results from overstimulation of D 1 receptors, and the administration of a the D 1 and D 2 families of dopamine receptors. The D 1 family is subdivided into D 1 and D 5 receptors, and the D 2 family selective D 2 agonist should correct this imbalance (Durif, 1999) . However, administration of a D 2 agonist has been and light (12 h light/12 h dark cycle), food and water were available ad libitum, and the care of the animals was reported as being able to induce dyskinesia in levodopanaive monkeys treated with 1-methyl-4-phenyl-1,2,3,6-supervised by veterinarians skilled in the health-care and maintenance of non-human primates. Experiments were tetrahydropyridine (MPTP) (Gomez-Mancilla and Bedard, 1992) .
carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) for Whereas the electrophysiological investigation of dyskinesia is obviously difficult at the striatal level, some the care of laboratory animals. All efforts were made to minimize animal suffering and to use the smallest number investigators are taking an interest in recording GPi activity, as this is the main basal ganglia output structure receiving of animals necessary to produce reliable scientific data. The animals were killed at the end of the experiments, and striatal information through the direct and indirect pathways (Alexander and Crutcher, 1990; DeLong, 1990) . The histochemical investigation of the brains showed a marked decrease in the number of tyrosine hydroxylaseadministration of levodopa and apomorphine to MPTP-treated monkeys (Filion et al., 1991; Boraud et al., 1998; immunoreactive neurones (method of Bezard et al., 1997) in the substantia nigra of both experimental monkeys (78.2 and 1999) or to parkinsonian patients (Hutchinson et al., 1997; Stefani et al., 1997; Merello et al., 1999a, b; 81.1% reduction) compared with the control values in the third, untreated monkey. 2000) has been shown to reduce GPi firing frequency to a level considerably lower than in the normal animals, even in the absence of dyskinesia. Conversely, deep-brain stimulation and the administration of riluzole, both of which are known to
Surgery and MPTP administration
A recording chamber was attached stereotactically under improve the parkinsonian motor syndrome without inducing dyskinesia (Benazzouz et al., 1995; Gross et al., 1997) , general anaesthesia [ketamine hydrochloride 10-15 mg/kg i.m. (intramuscularly) (Panpharma, Fougères, France) and restore GPi activity close to the normal level (Boraud et al., 1996 (Boraud et al., , 2000b . xylazine 1.5-2.5 mg/kg i.m., Sigma, St Louis, MO, USA] at an angle of 45°to the sagittal plane to facilitate the positioning A correlation between an excessive decrease in GPi discharge frequency and the appearance of levodopa-induced of the microelectrodes, which were then inserted parallel to the central axis of the chamber, as described previously dyskinesia has been established recently in the MPTP-treated monkey by Papa and colleagues . However, (Boraud et al., 1996 (Boraud et al., , 1998 (Boraud et al., , 2000a . Monkeys were made severely parkinsonian by bilateral intracarotid injection of an these investigators focused only on the change in firing frequency, although modifications in the neuronal firing acute dose of MPTP (0.8 mg/kg each side) under arteriographic control, as described previously (Benazzouz pattern have also been hypothesized to be involved (Obeso et al., 2000) . Moreover, although this correlation affords et al., 1993). significant new insights, Papa and colleagues restricted their study to the effect of levodopa. Thus, it has not yet been possible to clarify what role the direct pathway may have in
Behavioural assessment
The animals' behaviour was assessed on a clinical scale for the genesis of levodopa-induced dyskinesias. To do this, it would be necessary to look at the effects of D 1 and D 2 parkinsonian monkeys (Imbert et al., 2000) , which rates the following symptoms of parkinsonian disability: tremor (0-receptor agonists on the discharge characteristics of both parts of the pallidal complex (GPe and the GPi).
3); variation in the general level of activity (0-3); body posture (flexion of spine, 0-3); vocalization (0-2); freezing Therefore, we studied the effect of the administration of prodyskinetic doses of three dopaminergic agonists-(0-2); and frequency of arm movements (reaching for food, 0-3 for each upper limb). Rigidity (0-3 for each upper limb) apomorphine (a mixed D 1 /D 2 agonist), SKF-38393 (a D 1 agonist) and piribedil (a D 2 /D 3 agonist)-on the single-unit was assessed at the end of each session in order not to interfere with assessment of the general level of activity. The activity of pallidal neurones in normal and MPTP-treated monkeys. maximum disability score was 25. Dyskinesias were also rated on the scale published by Benazzouz and colleagues (Benazzouz et al., 1995) . The following items were assessed: frequency (0-3); nausea (0-1); and overall level of activity
Material and methods
(from -2 to ϩ2). The normal score was 0, the minimum dyskinesia score -2 and the maximum dyskinesia score 6.
Animals
Experiments were conducted on two female cynomolgus The clinical modifications induced by each drug were assessed (i) during regular sessions of direct behavioural evaluation monkeys (Macaca fascicularis; CRP, Port Louis, Mauritius) aged 3 and 3.5 years and weighing 2.7 and 3.1 kg, respectively. and (ii) during each electrophysiological recording session, immediately after each recording. In the assessments made A third cynomolgus monkey, matched for age, sex and weight, was used for histological controls. The animals during the regular sessions of direct behavioural evaluation, two examiners observed the animal moving freely around its were housed in individual primate cages under controlled conditions of humidity (50 Ϯ 5%), temperature (24 Ϯ 1°C) cage and evaluated its motor performance, coaxing it to perform various tasks by offering appetizing fruit, and a third Drugs examiner, watching a simultaneous video recording, made a Apomorphine (Apokinon ® ; Aguettant, Lyon, France), a nonblind, independent assessment. Rating notes were compared selective agonist of dopamine receptors, was injected regularly in order to eliminate observer bias (Taylor et al., subcutaneously at a dose (0.1 mg/kg) known to induce 1994). In the assessments made during each electrodyskinesia in MPTP-treated animals (Kuno, 1997) . SKFphysiological recording session, the clinical evaluation was 38393 (RBI, Natick, Mass., USA), an agonist of the D 1 limited to the rigidity and arm movement items of the receptor, was administered intramuscularly at a dose (1.5 mg/ disability scale, plus the dyskinesia scale. The evaluation kg) known to induce hyperkinesia in MPTP-treated animals was made every 5 min and continued until performance (Jenner, 1995) . Piribedil (Trivastal ® , Eutherapie, Neuilly sur scores returned to preinjection levels. Seine, France), an agonist of D 2 /D 3 receptors, was injected intramuscularly at a dose (3 mg/kg) known to induce dyskinesia in MPTP-treated animals (Smith et al., 1996) .
Electrophysiological recording
After the first set of tests with these drugs, the animals were Extracellular unit recordings were performed in calm, awake treated with MPTP as described above to render them monkeys, in the absence of voluntary movements, as severely parkinsonian. The tests were then repeated with the described previously (Boraud et al., 1996 (Boraud et al., , 1998 (Boraud et al., , 2000a .
same drugs. Animals were seated in a recording chair and tungsten electrodes (FHC, 6-8 MΩ) were lowered using a microdrive (OM 951, Narishige, Tokyo, Japan). Each recording lasted
Data analysis 10 s (2000 interspike intervals). After signal amplification
A one-way ANOVA (analysis of variance) with repeated through a differential preamplifier (Model 113; Princeton measures was used to compare mean firing frequencies. Applied Research, Princeton, Mass., USA) and spike When significant, the ANOVA was followed by a post hoc discrimination (N-750 Spike Analyser; Mentor), data were Dunnett multiple comparison test. The results for the two processed on-line through a computer (Power PC 6400; Apple animals were pooled after the ANOVA had shown they were Cupeatine, Calif., USA) programmed to stock sequences of not different (P Ͼ 0.5). The 'best effect' values of each interspike intervals via a custom-made interface. A time agonist on firing frequency in 'normal' animals and after interval histogram was constructed from each recording. We MPTP treatment were compared using Student's t test. Mean then charted a density histogram for each cell, according to 'on' values (firing frequency during the period when the the method described by Kaneoke and Vitek (Kaneoke and animal presented a clinical amelioration without dyskinesia) Vitek, 1996) , to determine the firing pattern (random, regular and mean 'dyskinesia' values (firing frequency during or bursting) as described previously (Boraud et al., 1998) . dyskinesia) were pooled for all three agonists and compared Marking lesions were made by passing DC (30 µA for 10 s) using the paired t test. In order to compare firing patterns, through the recording electrode at selected points. These we analysed the frequency of distribution of the different were then used, together with electrophysiological landmarks patterns (χ 2 (2), P Ͻ 0.05 when χ 2 Ͼ 5.991) according to and the dark lines of gliosis that indicated recording tracks the method described by Mushiake and colleagues (Mushiake in the pallidal complex, to retrace the anatomical path of et al., 1991) . This comparison was made for each 2000-spike electrode penetration and the locations of the neurones that recording. were recorded (data not shown).
A correlation matrix was then built for each agonist and The activity of the neurone was first isolated from each structure (GPi and GPe) to identify possible correlations background noise, and its activity was recorded three times between clinical and electrophysiological parameters. For over a period of~20 min before the injection of any drug; each recording, we calculated the correlation coefficient for this gave us a basal value for each drug. After injection of the following variables: (i) the number of neurones whose the agonist, the same neurone was then recorded every 5 min mean firing frequency was significantly modified compared until it returned to the basal value. The value of n for each with the normal state; (ii) the number of neurones with a pharmacological situation indicates the number of fully significantly modified firing pattern; (iii) the number of times evaluated neurones, i.e. approximately 40-50% of the total the animal presented a significant clinical modification; and number of recorded cells in the normal situation and only (iv) the number of times dyskinesias were observed. Items 10-15% in the MPTP situation. The three recordings that were considered correlated when P Ͻ 0.05. deviated most from the basal value were pooled to give the 'best effect' value for each drug. The 'on' value, where applicable, was the mean firing frequency recorded during Results the period when the animal presented clinical amelioration without dyskinesia. The 'dyskinesia' value was the mean
Before MPTP administration
As expected (Boyce et al., 1990; Nutt, 1990; Durif, 1999) , firing frequency recorded during the period when the animal presented dyskinesia. For the 'on' and 'dyskinesia' values, no noticeable behavioural change or dyskinesia was observed for any of the agonists tested, whereas there were results were pooled for all three agonists. modifications in the electrophysiological activity of the firing frequency [F(13,265) ϭ 48.7, P Ͻ 0.0001, n ϭ 19 pallidal complex. cells] 10 min after administration (P Ͻ 0.05). The firing pattern was also significantly modified (increase in the number of regular neurones) for 10 min (P Ͻ 0.05). The effects lasted a total of 30 min.
GPe (Fig. 1) The D 2 /D 3 agonist induced a significant increase in mean Mean firing frequency [F(13,223) ϭ 38.5, P Ͻ 0.0001, n ϭ firing frequency [F(13,335) ϭ 41.2, P Ͻ 0.0001, n ϭ 24 16 cells] decreased significantly 5 min after administration cells] 10 min after administration. This increase (P Ͻ 0.05) of the non-selective dopaminergic agonist apomorphine lasted 10 min and was followed by a sharp decrease lasting (P Ͻ 0.05) and recovered its normal level 45 min later. There 20 min. The effects lasted a total of 40 min. There was no was no modification of the firing pattern.
Injection of the D 1 agonist significantly decreased mean modification of the firing pattern. significant decrease (P Ͻ 0.01) and the firing pattern returned GPi (Fig. 2) to normal. Firing frequency was modified for a total of 80 min. Mean frequency [F(15,225) ϭ 37.1, P Ͻ 0.0001, n ϭ 16 cells] decreased significantly 15 min after injection of the non-selective dopaminergic agonist (P Ͻ 0.05). The firing After MPTP administration pattern presented a significant modification (increase in the Parkinsonian motor abnormalities were rated 15.2 Ϯ 3.8 in number of regular neurones) 10 min later (P Ͻ 0.05). These MPTP-treated animals and were diminished by all three effects lasted a total of 50 min.
agonists (apomorphine, 5.2 Ϯ 1.3; SKF-38393, 8.0 Ϯ 2.5; Administration of the D 1 agonist also affected mean piribedil, 5.6 Ϯ 1.7). The dopaminergic agonists induced frequency [F(17,341) ϭ 27.1, P Ͻ 0.001, n ϭ 19 cells], dyskinesias as expected with the doses used (apomorphine, which decreased significantly 5 min after injection (P Ͻ 0.05).
3.2 Ϯ 0.7; SKF-38393, 0.9 Ϯ 0.7; piribedil, 2.3 Ϯ 1.0). This was followed 5 min later by a significant modification (increase in the number of regular neurones) of the firing pattern (P Ͻ 0.05), which lasted 45 min. The effects lasted a total of 70 min.
GPe (Fig. 3) Mean firing frequency [F(17,143) ϭ 23.1, P Ͻ 0.0001, The D 2 /D 3 agonist induced a significant transient increase in mean frequency [F(25,571) ϭ 102.1, P Ͻ 0.0001, n ϭ n ϭ 8 cells] increased significantly 5 min after injection of apomorphine. This was followed 5 min later by a 22 cells] 5 min after administration (P Ͻ 0.05). This was followed 5 min later by a significant change (increase in the significant change (increase in the number of regular neurones) in the firing pattern (P Ͻ 0.05). The effects number of random neurones) in the firing pattern (P Ͻ 0.05). The increase in firing frequency was quickly followed by a stopped after 20 min. 'Best effect' values were significantly higher than those recorded before MPTP treatment followed 15 min later by a significant modification (increase in the number of random neurones) of the firing pattern (P Ͻ 0.05).
Administration of the D 1 agonist modified neither mean (P Ͻ 0.05). The effects stopped after 50 min. 'Best effect' values were significantly higher than in animals before frequency nor firing pattern [F(17,89) ϭ 1.2, n ϭ 5 cells]. 'Best effect' values were significantly higher than those MPTP treatment (P Ͻ 0.05). 'On' values were not significantly different from recorded before MPTP treatment (P Ͻ 0.05).
Injection of the D 2 /D 3 agonist affected mean frequency 'dyskinesia' values in GPe neurones. After injection of the non-selective agonist (Fig. 3 , top) [F(19,159) ϭ 17.8, P Ͻ 0.0001, n ϭ 8 cells], which increased significantly 10 min later (P Ͻ 0.05). This was or the D 2 /D 3 agonist (Fig. 3, bottom) , no correlation was The D 1 agonist also induced a significant decrease in the neurones. Nor was any correlation found between dyskinesia mean firing frequency [F(23,263) ϭ 29.2, P Ͻ 0.0001, n ϭ and the firing rate (respectively, r ϭ 0.2182, P Ͻ 0.05 if 11 cells] 5 min after injection (P Ͻ 0.05). This was followed r Ͼ 0.5760; r ϭ 0.3443, P Ͻ 0.05 if r Ͼ 0.4973) or the 15 min later by a significant modification (increase in the firing pattern (r ϭ 0.0000 and r ϭ 0.0006, respectively).
number of random neurones) of the firing pattern (P Ͻ 0.05). The effects stopped after 80 min. There was no significant difference between the 'best effect' values obtained before and after MPTP treatment.
GPi (Fig. 4)
The D 2 /D 3 agonist significantly decreased mean frequency Administration of the non-selective dopaminergic agonist [F(23,263 ) ϭ 32.3, P Ͻ 0.0001, n ϭ 9 cells] 10 min after affected mean frequency [F(23,167) ϭ 57.4, P Ͻ 0.0001, administration (P Ͻ 0.05). This was followed 10 min later n ϭ 7 cells], which decreased significantly 5 min later by a significant modification (increase in the number of random neurones) of the firing pattern (P Ͻ 0.05). The (P Ͻ 0.05). This was followed 10 min later by a significant Moine et al., 1997) . Variations in the electrophysiological activity of neurones compared with basal conditions are indicated by a small arrow within the structure or the neurone population. Dark lines represent excitatory pathways and white lines inhibitory pathways. STN ϭ subthalamic nucleus; SNc ϭ substantia nigra pars compacta. effects stopped after 110 min. There was no significant agonist (Fig. 4, bottom) and modification of the firing rate (respectively, r ϭ 0.5000, P Ͻ 0.05 if r Ͼ 0.5760; r ϭ difference between 'best effect' values obtained before and after MPTP treatment.
0.5000, P Ͻ 0.05 if r Ͼ 0.5760; r ϭ 0.4714, P Ͻ 0.05 if r Ͼ 0.4973), whereas there was a correlation with A significant difference was observed between 'on' and 'dyskinesia' values in GPi cells (49.5 Ϯ 14.4 and modification of the firing pattern (r ϭ 1.00, r ϭ 1.00 and r ϭ 1.00, respectively). 35.7 Ϯ 17.6 Hz, respectively; P Ͻ 0.05).
Correlations were found between clinical improvement after injection of the non-selective agonist (Fig. 4, top) , the D 1 agonist (Fig. 4, middle) and the D 2 /D 3 agonist (Fig. 4, 
Discussion
The present results shed light on the complex relationship bottom) and modification of the firing frequency of GPi neurones (respectively, r ϭ 1, P Ͻ 0.05 if r Ͼ 0.5760; r ϭ between the clinical improvement and dyskinesia provoked by dopamine replacement therapy on the one hand and the 1, P Ͻ 0.05 if r Ͼ 0.4973; r ϭ 1, P Ͻ 0.05 if r Ͼ 0.4973), but not modification of the firing pattern (r ϭ 0.5000, r ϭ electrophysiological parameters of globus pallidus neuronal activity on the other hand. This work confirms that a 0.4523 and r ϭ 0.4714, respectively). We found no correlation between dyskinesia after injection of the non-selective agonist correlation existed between clinical improvement and decrease in the firing frequency of GPi neurones and that the (Fig. 4, top) , the D 1 agonist (Fig. 4, middle) and the D 2 /D 3 onset of dyskinesias was correlated with a modification of of the D 2 /D 3 agonist was not reflected in any clinical effect. This may be explained by the fact that firing frequency did the firing pattern associated with an excessive decrease in firing frequency. Also, both receptor families may be involved not reach a pathological level (Bezard et al., 1999) . In MPTPtreated monkeys, all three agonists induced a marked decrease in the genesis of dyskinesia, since both D 1 and D 2 agonists induced the above side-effects.
in GPi firing frequency. These results also confirm the data already obtained in humans and in MPTP-treated monkeys (Filion et al., 1991; Hutchinson et al., 1997; Stefani et al., 1997) .
Methodological considerations
It thus appears that, whereas the segregation of a D 1 or Whether the changes in the electrophysiological activity of direct pathway from a D 2 or indirect pathway would fit well pallidal neurones we report are representative of the action with the pathological situation, it would not fit with the of dopamine agonists on the whole pallidal complex is normal situation. Similar observations have led some authors obviously critical to the significance of the present results.
to dispute the existence of D 1 /D 2 segregation (Surmeier et al., Baseline firing frequencies and pattern distributions of both 1996). However, it is plausible that systemic (subcutaneous the GPe and GPi neurones we recorded in normal and MPTPor intramuscular) administration of dopamine agonists may treated monkeys are similar to those in recordings published act on different structures in the basal ganglia, given that previously (Filion and Tremblay, 1991; Bergman et al., 1994;  dopamine receptors have been described in other basal ganglia Boraud et al., 1998 Boraud et al., , 2000a . The sample size of recorded nuclei (Mansour et al., 1990; Caillé et al., 1996 ; Levant, neurones in each situation ensures the statistical validity of 1998; Hassani and Feger, 1999) . The results obtained by Le this comparison (GPe: normal, n ϭ 59; MPTP, n ϭ 21; GPi:
Moine and colleagues may help to clarify the interpretation normal, n ϭ 57; MPTP, n ϭ 27). However, whereas baseline of our data. They showed that expression of c-fos, an index characteristics represent a sample of the population of all of the level of activity of a structure, can be activated through pallidal neurones in the population of all monkeys, changes D 1 and inhibited through D 2 receptors in both striatal output in neuronal activity induced by dopamine agonists can only pathways ('direct' and 'indirect') in normal rats (Le Moine be interpreted as representing a sample of cells from the et al., 1997). According to these authors, this paradoxical populations within these two monkeys. Nevertheless, influence could be explained by the fact that the D 1 agonist although the value of n for each pharmacological agent may acts at the level of the substantia nigra (Fig. 5 ) on presynaptic appear to be unsatisfactory, it indicates the number of D 1 receptors located on GABAergic neurones connecting fully evaluated neurones, i.e. from before dopamine agonist back to dopaminergic cells (Caillé et al., 1996) . This would injection until return to baseline activity, which represents decrease dopaminergic release in the striatum, inducing 40-50% of the total number of recorded cells in monkeys disinhibition of the activity of D 2 neurones, which would, in before MPTP treatment and only 10-15% in monkeys after turn, have an inhibitory influence at GPe level. This MPTP treatment.
hypothesis fits in well with our results, as this effect was cancelled in our animals by dopaminergic depletion. The fact that, in the study of Le Moine and colleagues, the D 2
Can the present data be explained by the agonist induced a decrease in c-fos expression supports our observations. Indeed, they killed the rats 1 h after injection current model of basal ganglia organization?
The changes affecting the electrophysiological activity of the of the agonist (Le Moine et al., 1997) , which corresponds to the first phase of our recordings. The later paradoxical GPe in normal animals seem to contradict the current model of basal ganglia function, which postulates that there is no decrease in firing frequency could be explained by the inhibitory influence that the D 2 agonist exercises on D 2 interaction between the direct D 1 -dependent and the indirect D 2 -dependent pathways. Indeed, both apomorphine (the nonpresynaptic receptors, decreasing dopaminergic inhibition of the GABAergic neurones of the indirect pathway, thus selective agonist) and SKF-38393 (the D 1 agonist) induced a noticeable decrease in GPe firing frequency, whereas increasing the inhibitory input to the GPe. piribedil (the D 2 /D 3 agonist) induced a short increase followed by a longer decrease. The data from MPTP-treated animals were, in contrast, consistent with the classical model of basal
Both D 1 and D 2 agonists induced dyskinesias
Our results confirm that dopamine depletion is a necessary ganglia function. The D 1 agonist induced no modification of GPe discharge frequency, whereas both the non-selective condition for the emergence of dyskinesia (Boyce et al., 1990; Nutt, 1990; Durif, 1999) . Indeed, no behavioural agonist and the D 2 /D 3 agonist induced an increase in the firing rate. These results are in accordance with data obtained changes were observed in the 'normal' monkeys, whereas in the MPTP-treated animals all three agonists induced from parkinsonian patients (Hutchinson et al., 1997; Stefani et al., 1997) and MPTP-treated animals (Filion et al., 1991) . dyskinesia. However, the dyskinesias provoked by SKF-38393 (the D 1 agonist) were less severe than those provoked All three dopamine agonists induced, in the 'normal' animals, a decrease in the firing rate of GPi neurones. The slight by the non-selective agonist and the D 2 /D 3 agonist. Because both D 1 and D 2 agonists appear to generate dyskinesia, it is biphasic increase in firing frequency observed after injection not possible, from our data, to posit a link between dyskinesia normal monkeys, but they did provoke a significant decrease in firing frequency. Although the firing frequencies and a pharmacological stimulation of either the direct pathway or the indirect pathway. Such a correlation has been proposed of GPi neurones thus become similar in 'normal' and MPTP-treated animals whatever the agonist administered, (Blanchet et al., 1995 (Blanchet et al., , 1996 but other studies suggest that the mode of stimulation of dopamine receptors may be the the behaviours that are exhibited are far from similar. Therefore, the concept of excessive decrease in neuronal most important factor. These reports indicate that continuous dopaminergic stimulation is best for the optimal regulation activity in the GPi should be used with caution, and only with reference to the decrease observed in the 'best on' of the basal ganglia circuit (Goulet et al., 1996 (Goulet et al., , 1997 .
situation. Thus, changes in pattern distribution would certainly play the crucial role in levodopa-and dopamine agonist-induced dyskinesias. This also questions the need
Dyskinesias are correlated to changes in GPi
for dopamine depletion in the emergence of dyskinesia.
neuronal activity
Further studies on the physiopathology of dyskinesias must Whereas no correlation has been established between take into account the present results, especially those electrophysiological parameters of the GPe and clinical regarding firing patterns, in order to elucidate the improvement, with or without dyskinesia, change in mechanisms of their origin. neuronal activity in the GPi has been linked to the genesis of dyskinesia. Indeed, there was a correlation with modification of the firing pattern, although this was not treated with apomorphine. Although Lozano and colleagues proposed an interesting model of dopaminergic drugBenazzouz A, Boraud T, Dubédat P, Boireau A, Stutzmann JM, induced dyskinesias based on changes affecting mainly the Gross C. Riluzole prevents MPTP-induced parkinsonism in the firing frequency (Lozano et al., 2000) , our present results rhesus monkey: a pilot study. Eur J Pharmacol 1995; 284: 299-307. stress the need to associate changes in firing frequency this is in comparison with the 'best on' situation. All the Eur J Neurosci 1999; 11: 2167-70. previous studies have been done either in MPTP-treated Blanchet PJ, Gomez-Mancilla B, Di Paolo T, Bédard PJ. Is striatal monkeys (Filion et al., 1991; Boraud et al., 1998 ; Papa dopaminergic receptor imbalance responsible for levodopa-induced et al., 1999) or in parkinsonian patients (Hutchinson et al., dyskinesia? [Review] . Fundam Clin Pharmacol 1995; 9: 434-42. 1997; Stefani et al., 1997; Merello et al., 1999a, b; Lozano et al., 2000) . The present study is the first that has also Blanchet PJ, Grondin R, Bedard PJ. Dyskinesia and wearing-off recorded the effects of dopaminergic agonists on the following dopamine D1 agonist treatment in drug-naive 1-methylpallidal activity of normal monkeys. These agonists did 4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 1996; 11: 91-4. not induce any behavioural abnormality or dyskinesia in
